• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 7, 2022

View Archived Issues
Novavax logo, coronavirus vaccine vials

Novavax COVID-19 vaccine wins adcom support

Given the safety and efficacy data presented June 7 for Novavax Inc.’s COVID-19 vaccine, NVX-CoV2373, it came as no surprise when the U.S. FDA’s Vaccines and Related Biologic Products Advisory Committee voted 21-0, with one abstention, to support an emergency use authorization for the vaccine, which is already approved and being used in many other countries, including the EU and Canada. Read More

Immunos adds $74M in series B round to progress myeloid checkpoint inhibitors

Immunos Therapeutics AG closed a $74 million series B round to progress its first-in-class, multifunctional immuno-oncology drug candidate, IOS-1002, and to expand further its pipeline of biologic drugs based on immuno-stimulatory human leukocyte antigen molecules. Read More
Businesswoman pressing dollar sign on touchscreen

Code raises a series A to develop Duchenne and diabetes therapies

Code Biotherapeutics Inc. has raised an upsized and oversubscribed series A financing to develop programs for treating rare and genetic diseases that include Duchenne muscular dystrophy and type 1 diabetes. Read More

CALD shoulder in briefing docs for Bluebird’s eli-cel no surprise as beti-cel makes grade

Wall Street took in stride mixed FDA briefing documents with regard to the upcoming adcom review of Bluebird Bio Inc.’s two gene therapy prospects, and shares of the company (NASDAQ:BLUE) closed at $3.61, up 63 cents, or 21%. Read More
Magnifying glass, FDA concept image

US FDA’s accelerated approvals: Time to reform?

The U.S. FDA’s accelerated approval path is front burner these days, what with Congress looking to modernize the path through provisions added to the must-pass user fee legislation, the controversy still boiling over the FDA’s accelerated approval last year of Biogen Inc.’s Alzheimer’s drug, Aduhelm (aducanumab), and a number of recent withdrawals of drugs granted accelerated approval years ago. Read More
Lung cancer illustration

Henlius’ PD-1 drug shows positive data in phase III trial to treat ES-SCLC

Shanghai Henlius Biotech Inc.’s anti-PD-1 monoclonal antibody serplulimab has generated positive data in a phase III trial as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Read More
FDA-approve-green.png

Three NMEs added, but US approvals are at five-year low

Global regulatory activity has fallen slightly, partially due to a decline in pandemic activity, and U.S. FDA approvals of drugs and biologics are at their lowest levels in five years. Read More

The BioWorld Insider Podcast: New therapies vie to change fatal course of amyotrophic lateral sclerosis

As multidisciplinary care extends survival and improves the quality of life for people with amyotrophic lateral sclerosis (ALS), can a host of new ALS drugs vying to slow its progression make a difference? Join the BioWorld Insider podcast as we discuss what the future of medicine may hold for ALS patients. Read More

Appointments and advancements for June 7, 2022

New hires and promotions in the biopharma industry, including: Adarx, Alpine Immune, Athira, Awakn, Brooklyn, Cytovia, Emergence, Forte, Immunomic, Inozyme, NLS, Prolacta, Regenxbio, Targimmune. Read More

Conference data for June 7, 2022: ADA

New and updated preclinical and clinical data presented by biopharma firms at the American Diabetes Association's 82nd Scientific Sessions, including: Lilly, Sernova, Vertex, Zealand. Read More

Conference data for June 7, 2022: ASCO

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Adicet, Akeso, Alphamab, Amgen, Anheart, Arcellx, Astrazeneca, Atara, Aveo, Ayala, Biontech, BMS, Carsgen, Centessa, Clovis, CG, Corcept, Cstone, Curis, Cyteir, Effector, Eisai, Enterome, Gilead, Henlius, Immunocore, Immutep, In8bio, Innovent, Intensity, Jacobio, Janssen, JW, Kite, Legend, Linnaeus, Mei, Menarini, Merck, Mirati, Nanobiotix. Read More

Financings for June 7, 2022

Biopharmas raising money in public or private financings, including: Cimcure, Concert, Coya, Evaxion, Inmed, Pinetree, Rockwell. Read More

In the clinic for June 7, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Assembly, Arbutus, Corcept, Harmony, Innocare, Medexus, Neurocrine, Newamsterdam, Praxis, Verastem. Read More

Other news to note for June 7, 2022

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aslan, Bavarian, Editas, Find, Immatics, Kiromic, Microbion, MRM, SATT. Read More

Regulatory actions for June 7, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Amgen, Antengene, Aum, Biocryst, Biondvax, BMS, Clarity, Cstone, Enlivex, GBT, Iaso, Innovent, Lexaria, Pfizer, Revive, Senhwa, Sensorion, Sifi, Veru. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe